$118 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 12 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CDLX | Cardlytics, Inc. | $42,476,000 | +53.6% | 2,552,626 | 0.0% | 35.95% | +21.8% | |
| FATE | Sell | Fate Therapeutics, Inc. | $25,884,000 | +10.7% | 1,473,186 | -19.2% | 21.90% | -12.3% |
| KALA | Kala Pharmaceuticals, Inc. | $15,362,000 | +69.1% | 1,857,582 | 0.0% | 13.00% | +34.1% | |
| STIM | Sell | Neuronetics, Inc. | $11,320,000 | -29.1% | 742,289 | -10.0% | 9.58% | -43.8% |
| SELB | Buy | Selecta Biosciences, Inc. | $6,573,000 | +53.8% | 2,773,479 | +72.6% | 5.56% | +21.9% |
| XFOR | New | x4 Pharmaceuticals Inc | $5,423,000 | – | 311,492 | +100.0% | 4.59% | – |
| TTOO | T2 Biosystems, Inc. | $4,844,000 | -12.6% | 1,841,924 | 0.0% | 4.10% | -30.7% | |
| TRVN | Trevena, Inc. | $3,204,000 | +262.9% | 2,053,540 | 0.0% | 2.71% | +187.5% | |
| GNCA | Genocea Biosciences, Inc. | $1,161,000 | +105.5% | 1,968,606 | 0.0% | 0.98% | +63.0% | |
| LIFE | Atyr Pharma Inc. | $1,006,000 | +11.0% | 1,827,992 | 0.0% | 0.85% | -12.0% | |
| DARE | Dare Bioscience, Inc. | $457,000 | +97.0% | 326,243 | 0.0% | 0.39% | +56.0% | |
| PULM | Sell | Pulmatrix, Inc. | $456,000 | -47.2% | 359,438 | -90.0% | 0.39% | -58.1% |
| ASNS | Exit | Arsanis, Inc. | $0 | – | -1,868,957 | -100.0% | -4.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2019-06-28
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Fate Therapeutics, Inc. | 30 | Q2 2021 | 79.2% |
| Atyr Pharma Inc. | 26 | Q3 2021 | 15.1% |
| Trevena, Inc. | 22 | Q2 2019 | 24.9% |
| Genocea Biosciences, Inc. | 21 | Q1 2019 | 32.5% |
| Selecta Biosciences, Inc. | 20 | Q1 2021 | 39.5% |
| T2 Biosystems, Inc. | 20 | Q2 2019 | 36.1% |
| Dare Bioscience, Inc. | 17 | Q3 2021 | 3.9% |
| Pulmatrix, Inc. | 16 | Q1 2019 | 15.4% |
| Cerulean Pharma Inc | 13 | Q2 2017 | 16.2% |
| Kala Pharmaceuticals, Inc. | 11 | Q1 2020 | 37.1% |
View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2022-03-30 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-12 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-12 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-12 |
| 13F-HR | 2020-05-14 |
| 4 | 2020-05-06 |
| 3 | 2020-04-30 |
View Polaris Venture Management Co. V, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.